Skip to content

Study · Randomized controlled trial · n = 52 · 2008

1 result

Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.

Pirl WF, Greer JA, Goode M, Smith MR

Psycho-oncology1 Feb 2008Cited by 49 (Europe PMC)

PMID17443645 (opens in a new tab)PMCIDPMC3047392 (opens in a new tab)DOI10.1002/pon.1206 (opens in a new tab)PepBankPUB-17443645
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In men with advanced or recurrent prostate cancer, depression did not differ significantly between leuprolide and bicalutamide.

    In plain wordsIn men with prostate cancer, depression did not differ significantly between leuprolide and bicalutamide.

    Peptide
    Leuprolide
    Outcome
    No significant changeDepression
    Study

    n = 52

    Comparator
    Bicalutamide
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · parenteralAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in depression between the two types of hormone therapy.
    2 context sentences
    Summary · context
    Fifty-two men with advanced or recurrent prostate cancer were randomly assigned to receive either parenteral leuprolide or oral bicalutamide.
    Summary · context
    Patients completed the Beck Depression Inventory (BDI) and Fatigue Severity Scale (FSS) at pretreatment baseline, 6 months, and 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.